ストックスクリーナーアプリを入手
9.03
0.11%
-0.010
アフターアワーズ：
8.99
-0.04
-0.44%
Aurinia Pharmaceuticals Inc (AUPH) 最新ニュース
(AUPH) On The My Stocks Page - Stock Traders Daily
Layoff Tracker: Editas Will Cut 60% of Staff - BioSpace
Short Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Declines By 9.6% - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Rating Lowered to "Buy" at StockNews.com - MarketBeat
Charles Schwab Investment Management Inc. Grows Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharma Surges Pre-Market After Director Kevin Tang Discloses $10M Stock Buy: Retail Confidence Spikes - MSN
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Held Back By Insufficient Growth Even After Shares Climb 25% - Simply Wall St
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options - MSN
Aurinia Pharma stock hits 52-week high at $9.76 - Investing.com
Aurinia Pharma stock hits 52-week high at $9.76 By Investing.com - Investing.com UK
Kevin Tang buys $10.82 million in Aurinia Pharmaceuticals shares - Investing.com India
Kevin Tang buys $10.82 million in Aurinia Pharmaceuticals shares By Investing.com - Investing.com Australia
(AUPH) Investment Analysis - Stock Traders Daily
While institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownership - Yahoo Finance
We Might See A Profit From Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Soon - Simply Wall St
PDT Partners LLC Buys 130,204 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by Algert Global LLC - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Invests $3.33 Million in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates - MSN
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis - sharewise
Aurinia's LUPKYNIS Named First-Line Treatment in 2024 ACR Lupus Nephritis Guidelines - StockTitan
(AUPH) Technical Pivots with Risk Controls - Stock Traders Daily
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Position Reduced by GSA Capital Partners LLP - MarketBeat
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024 - sharewise
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ARMISTICE CAPITAL, LLC's Strategic Reduction in Aurinia Pharmace - GuruFocus.com
Aurinia to Participate in Jefferies London Healthcare Conference - sharewise
Aurinia Pharmaceuticals Engages at London Conference - TipRanks
Aurinia Pharmaceuticals director Karen Smith sells $44,181 in stock - Investing.com India
Aurinia Pharmaceuticals director Karen Smith sells $44,181 in stock By Investing.com - Investing.com Nigeria
Aurinia Pharmaceuticals director sells shares valued at $38,415 - Investing.com India
Aurinia Pharmaceuticals director sells shares valued at $38,415 By Investing.com - Investing.com Canada
Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded at StockNews.com - Defense World
Aurinia Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Aurinia stock jumps 14% on Q3 earnings, restructuring announcement - MSN
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):